Adjunctive Benzodiazepine Treatment Of Hospitalized Schizophrenia Patients In Asia From 2001 To 2008
Phern-Chern Tor,Tze Pin Ng,Kian-Hui Yong,Kang Sim,Yu-Tao Xiang,Chuan-Yue Wang,Edwin Ho Ming Lee,Senta Fujii,Shu-Yu Yang,Mian-Yoon Chong,Gabor S Ungvari,Tianmei Si,Yan Ling He,Eun Kee Chung,Kok-Yoon Chee,Jintendra Trivedi,Pichet Udomratn,Naotaka Shinfuku,Ee Heok Kua,Chay Hoon Tan,Norman Sartorius,Ross J Baldessarini
DOI: https://doi.org/10.1017/S146114571000163X
2011-01-01
Abstract:Benzodiazepines are commonly prescribed to patients with schizophrenia in many countries, but as little is known about such treatment in Asia, we evaluated their adjunctive use for 6761 in-patients diagnosed with schizophrenia in nine Asian countries using a cross-sectional study design in 2001, 2004 and 2008. Multivariate logistic regression and multivariate linear regression analyses were performed to assess predictors of benzodiazepine use and dose, respectively. Overall, 54% of the patients received adjunctive benzodiazepines at an average daily dose equivalent to 30.3 mg diazepam, with minor changes over the years sampled. Benzodiazepine use was highest in Taiwan and Japan, lowest in Thailand and China, and was associated with fewer years ill, presence of delusions (OR 1.24), hallucinations (OR 1.22), disorganized speech (OR 1.17), social or occupational dysfunction (OR 1.16), and use of mood stabilizers (OR 3.15), antiparkinsonian (OR 1.79) or antidepressant drugs (OR 1.33), and lower doses of antipsychotics (all p = 0.016 to < 0.001). Benzodiazepine doses were highest in Taiwan and China, lowest in Korea and Singapore; higher doses were associated with being young, male, physically aggressive, receiving mood stabilizers, and having electroconvulsive treatment (all p = 0.019 to < 0.001). Benzodiazepine use was associated with neurological and systemic adverse effects. In conclusion, benzodiazepine use was common in Asian patients with schizophrenia. Predictors of benzodiazepine use and dose differed in this population. Critical clinical guidelines should be developed specifically for Asian countries to address sound practices in regard to use of benzodiazepines for psychotic disorders.